Chih‐Yi Liao

Capital Medical University — China

Medicine · Health Sciences

14h-index1.1kcitations128works5.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cholangiocarcinoma and Gallbladder Cancer Studies(23), Gastric Cancer Management and Outcomes(19), Neuroblastoma Research and Treatments(19), Neuroendocrine Tumor Research Advances(18), Lung Cancer Research Studies(16)

Publications128 total

Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial
˜The œLancet. Gastroenterology & hepatology·2025· 1 cited
Data from Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring <i>IDH1</i> or <i>IDH2</i> Mutations
2025Open Access
Supplementary Data 1 from Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring <i>IDH1</i> or <i>IDH2</i> Mutations
2025Open Access
Abstract C095: [212Pb]VMT-a-NET for somatostatin receptor subtype 2 (SSTR2)-expressing tumors: safety and preliminary efficacy results in patients with advanced neuroendocrine tumors (NETs)
Molecular Cancer Therapeutics·2025
Evaluating the role of postoperative long-acting somatostatin analog therapy in patients with metastatic neuroendocrine tumors undergoing surgical debulking
Surgery·2025
Patient reported outcomes in physical, cognitive, and reproductive and sexual health between early onset and average onset gastrointestinal cancers.
JCO Oncology Practice·2025
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring <i>IDH1</i> or <i>IDH2</i> Mutations
Clinical Cancer Research·2025· 1 cited
Surgical debulking versus non-surgical management for the control of carcinoid syndrome in metastatic small bowel neuroendocrine tumors.
Journal of Clinical Oncology·2025
[ <sup>212</sup> Pb]VMT-α-NET therapy in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs): Dose-limiting toxicity (DLT) observation participants after 1 year follow-up and preliminary report for expansion participants.
Journal of Clinical Oncology·2025· 2 cited
Abstract 4352: Safety and pharmacokinetics of tinengotinib monotherapy in different doses and dosing schedules in advanced solid tumors
Cancer Research·2025· 1 cited
Abstract 825: Correlation of clinical and biomarker data in FGFR inhibitor failed metastatic cholangiocarcinoma patients with tumor response to tinengotinib
Cancer Research·2025
DOTATATE PET CT tumor volume as a predictor of surgical outcome in patients with metastatic gastroenteropancreatic neuroendocrine tumors
Surgical Oncology Insight·2025· 1 citedOpen Access
Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: A Phase II Study
Cancer Medicine·2025Open Access
MEN1/DAXX alterations are associated with improved overall survival and treatment response in patients with pancreatic neuroendocrine tumors
Endocrine Abstracts·2025
Peptide receptor radionuclide therapy versus capecitabine/temozolomide for the treatment of metastatic pancreatic neuroendocrine tumors
Endocrine Abstracts·2025
Patient-reported outcomes in physical, cognitive, and sexual health in early-onset gastrointestinal cancers (EOGIC).
Journal of Clinical Oncology·2025· 1 cited
Tinengotinib in patients with advanced, metastatic cholangiocarcinoma: Overall survival results and biomarker correlative analysis from a phase 2 clinical trial.
Journal of Clinical Oncology·2025· 1 cited
Aggressive resection of non-contrast-enhanced tumor provides varying benefits to glioblastoma, IDH-wildtype patients based on different clinical characteristics
Cancer Letters·2025· 7 citedOpen Access
Tinengotinib for Adult Patients with Advanced or Metastatic Cholangiocarcinoma: A Multicenter, Open-Label Phase 2 Trial
SSRN Electronic Journal·2025Open Access
Neuron-like lineage differentiation induced by exogenous Neurexin-1 as a potential therapeutic strategy for glioma
Cancer Letters·2024· 7 cited
page 1 of 7Next →

Frequent Co-authors

Blasé N. Polite(10), Anjana Pillai(9), Daniel V.T. Catenacci(8), Xavier M. Keutgen(7), Osman Ahmed(7), Namrata Setia(6), Theodore Karrison(6), Hedy L. Kindler(6), Do‐Youn Oh(6), Lipika Goyal(6), Qian Yu(6), John J. Fung(5), Kiran K. Turaga(5), Antoine Hollebecque(5), Mikin Patel(5), Ethan Ungchusri(5), Thuong Van Ha(5), Rushabh Gujarathi(5), Alexander I. Spira(4), Amit Mahipal(4)